Molecular Biosystems Inc. (MBI) announced Tuesday that it hasacquired exclusive worldwide rights from Dendritech Inc. andits affiliate Michigan Molecular Institute to use their patentedmolecules in the development and commercialization ofcontrast agents for magnetic resonance imaging, computerizedtomography and ultrasound.

Dendritech's technology consists of spherical syntheticpolymers whose dimensions and surface chemistry can beprecisely controlled during the manufacturing process. Usingthe specially designed molecules, MBI hopes to developcontrast agents that may be targeted to individual organs ofthe body. Shares in MBI (NYSE:MB) of San Diego closed at$17.88, down 13 cents a share.

(c) 1997 American Health Consultants. All rights reserved.

No Comments